Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low‐dose interferon alfa in patients with advanced renal cell carcinoma

The objective of this study was to independently evaluate the objective response rate of sorafenib and sorafenib plus low‐dose interferon‐alfa 2b (IFN) as frontline therapy in patients with metastatic renal cell carcinoma (mRCC).

[1]  D. Cella,et al.  Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  I. Melero,et al.  Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes , 2009, British Journal of Cancer.

[3]  C. Noelke,et al.  MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib , 2009, Molecular Cancer Therapeutics.

[4]  M. Ohh,et al.  Differential Dependence of Hypoxia-inducible Factors 1α and 2α on mTORC1 and mTORC2* , 2008, Journal of Biological Chemistry.

[5]  Brian Keith,et al.  HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. , 2008, Cancer cell.

[6]  P. Thall,et al.  A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. , 2008, The Journal of urology.

[7]  P. Brossart,et al.  Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. , 2008, Blood.

[8]  R. Song,et al.  Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation , 2008, Leukemia.

[9]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[10]  W. Rathmell,et al.  Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Tangen,et al.  Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Ravaud,et al.  A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon- α2a as first-line therapy in metastatic renal cell carcinoma , 2007 .

[13]  David B Seligson,et al.  Prognostic relevance of the mTOR pathway in renal cell carcinoma , 2007, Cancer.

[14]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[15]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[16]  P. Thall,et al.  Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. , 2006, Cancer.

[17]  R. Figlin,et al.  Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Figlin,et al.  Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Hainsworth,et al.  Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Atkins,et al.  Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  William R Sellers,et al.  TSC2 regulates VEGF through mTOR-dependent and -independent pathways. , 2003, Cancer cell.

[22]  B. Wiedenmann,et al.  Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. , 2003, Journal of the National Cancer Institute.

[23]  M. Oya,et al.  Elevated Akt activation and its impact on clinicopathological features of renal cell carcinoma. , 2003, The Journal of urology.

[24]  R. Motzer,et al.  Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  E. Lam,et al.  Inhibition of the Phosphoinositide 3-Kinase Pathway Induces a Senescence-like Arrest Mediated by p27Kip1 * , 2000, The Journal of Biological Chemistry.

[26]  B. Rini,et al.  Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  T. Tammela,et al.  Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  A. Giaccia,et al.  Inhibition of the anti-apoptotic PI(3)K/Akt/Bad pathway by stress. , 1998, Genes & development.

[29]  Lewis C Cantley,et al.  PI3K: Downstream AKTion Blocks Apoptosis , 1997, Cell.

[30]  C. Bucana,et al.  Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[31]  L. Chung,et al.  Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. , 1994, Cancer research.

[32]  Z. Ying,et al.  Checking the Cox model with cumulative sums of martingale-based residuals , 1993 .

[33]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[34]  S. Pocock,et al.  Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.